- Home
- OCSL vs SYRE Comparison
OCSL vs SYRE Comparison
Compare OCSL & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- SYRE
- Stock Information
- Founded
- OCSL 2007
- SYRE 2013
- Country
- OCSL United States
- SYRE United States
- Employees
- OCSL N/A
- SYRE N/A
- Industry
- OCSL Finance: Consumer Services
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- SYRE Health Care
- Exchange
- OCSL Nasdaq
- SYRE Nasdaq
- Market Cap
- OCSL 1.1B
- SYRE 1.1B
- IPO Year
- OCSL 2008
- SYRE 2016
- Fundamental
- Price
- OCSL $13.78
- SYRE $29.49
- Analyst Decision
- OCSL Hold
- SYRE Strong Buy
- Analyst Count
- OCSL 3
- SYRE 4
- Target Price
- OCSL $14.33
- SYRE $52.67
- AVG Volume (30 Days)
- OCSL 619.7K
- SYRE 621.3K
- Earning Date
- OCSL 11-18-2025
- SYRE 11-04-2025
- Dividend Yield
- OCSL 11.65%
- SYRE N/A
- EPS Growth
- OCSL N/A
- SYRE N/A
- EPS
- OCSL 0.39
- SYRE N/A
- Revenue
- OCSL $316,801,000.00
- SYRE N/A
- Revenue This Year
- OCSL N/A
- SYRE N/A
- Revenue Next Year
- OCSL $1.64
- SYRE N/A
- P/E Ratio
- OCSL $34.84
- SYRE N/A
- Revenue Growth
- OCSL N/A
- SYRE N/A
- 52 Week Low
- OCSL $12.44
- SYRE $10.91
- 52 Week High
- OCSL $16.53
- SYRE $29.78
- Technical
- Relative Strength Index (RSI)
- OCSL 57.31
- SYRE 76.58
- Support Level
- OCSL $13.17
- SYRE $23.01
- Resistance Level
- OCSL $13.66
- SYRE $25.42
- Average True Range (ATR)
- OCSL 0.23
- SYRE 1.73
- MACD
- OCSL -0.00
- SYRE 0.47
- Stochastic Oscillator
- OCSL 94.62
- SYRE 97.67
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.